HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER
Clinical trials for HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to stop early breast cancer in its tracks
Disease control Recruiting nowThis phase 3 trial is testing whether adding the targeted drug ribociclib to standard hormone therapy can help prevent invasive breast cancer from returning in people with HR+ HER2- early breast cancer. About 1,400 participants will receive the combination for up to 3 years. The …
Matched conditions: HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 20:00 UTC
-
New drug cocktail aims to shrink breast tumors before surgery
Disease control Recruiting nowThis Phase 2 trial tests whether adding entinostat to a two-drug regimen (dalpiciclib and letrozole) before surgery can better shrink tumors in women with HR-positive, HER2-negative early breast cancer. Sixty participants will receive either the three-drug combo or the standard t…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Blood test may spot breast cancer return before symptoms appear
Disease control Recruiting nowThis study tests whether a blood test that looks for cancer DNA (ctDNA) can find breast cancer returning earlier than usual scans or exams. About 976 people with HR-positive/HER2-negative early breast cancer who had surgery will give blood samples over time. If the test shows sig…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC